Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
March 12, 2015
Agenebio’s AGB101 enroute to phase III on back of aMCI phase II
Trying to translate discovery research and early clinical data into phase III success has proved the bane for drug developers working in Alzheimer’s disease. But executives at Agenebio Inc., which is gearing up to start a phase III study in the second half of this year with lead product AGB101, think their approach will be up to the task. For one,
